Cancer screening means to perceive cancer before symptoms appear. It includes urine tests, blood tests, DNA tests and other tests or medical imaging. It is classified into many types such as cervical cancer screening, prostate cancer screening, breast cancer screening, colorectal cancer screening, head & neck cancer screening, liver cancer, mouth cancer, abdominal cancer, lung cancer screening, thyroid cancer, testicular cancer, pancreatic cancer, and genetic cancer screening. Breast cancer is common cancer in females, in both urbanized and underdeveloped countries. The major screening tests are Pap smear (for cervical cancer) & human papillomavirus (HPV) tests, sigmoidoscopy, cancer antigen 125 (CA-125)tests, alpha-fetoprotein blood test, colonoscopy (colon cancer), low-dose helical computed tomography, Prostate-specific antigen (PSA test),transvaginal ultrasound and mammography (breast cancer).
According to study, “North America Cancer Screening Market (2018-2023)” some of the major companies that are currently operating in the North American cancer screening market are GE Healthcare, Thermo Fisher Scientific, Abbott Diagnostics, Siemens Healthcare GmbH, Roche Diagnostics, Qiagen, Hologic Inc. All these key players are concentrating on research & development (R&D) and incoming into associations with the government to enlarge regional access.
On the basis of type, the North America cancer screening market is segmented into breast Magnetic Resonance Imaging (MRI) Screening, mammography screening, and breast ultrasound screening. On the basis of technique type, the market is segmented into genetic, laboratory, biopsy, imaging, and endoscopy tests. Genetic tests include Next Generation Sequencing (NGS), biomarker testing and microarray techniques. Biopsy & cytology test includes CT-guided biopsy, bone marrow biopsy, needle biopsy, bone biopsy, surgical biopsy, and aspiration biopsy. Imaging techniques are sub-segmented into nuclear, mammography and ultrasound and many others. On the basis of the stage, the market is segmented into TNM stages, stages (0-4), prognostic factors and other staging systems. In addition, on the basis of end-user, the market is segmented into laboratories & independent physicians, hospitals, and clinics.
The National Cancer Institute (NCI) maintenances research, health information dissemination, training, and other activities associated with the causes, diagnosis, prevention, and treatment of cancer. In addition, Cancer Intervention and Surveillance Modeling Network (CISNET) is an association of NCI that use numerical modeling to improve understanding of cancer control interventions.
Some of the key benefits associated are less radical treatment needed, better outcome, reduced mortality & morbidity, cost savings, identification of high-risk groups & opportunities for intervention, improved prognosis, and many others. Apart from the advantages some of the major disadvantages are over the treatment of borderline abnormalities, resource costs of screening system and longer morbidity. Moreover, there are some of the risks associated unnecessary distress, increased testing, radiation, missed a diagnosis, history of inflammatory bowel disease (IBS), sedentary lifestyles, obesity, Lynch syndrome, false positives, and over treatments.
The cancer screening is driven by rising incidence of cancer cases, followed by growing awareness early recognition of breast cancer, rising technological advancements, increasing aging population followed the rise in funds for cancer treatment by the government. However, lack of transparency in medical procedures, lack of associated funding and stringent government regulations and many others.
During 2018-2023, the North America cancer screening market is anticipated to grow at a CAGR of 11.1% subsequent in annual proceeds of US$ 16.3 billion. In the upcoming years, it is estimated that the market to grow fast due to the rise in technological advancements and the growing incidence of cancer cases.
To know more, click on the link below:-
https://www.kenresearch.com/healthcare/medical-devices/north-america-cancer/172429-91.html
Related Reports:-
https://www.kenresearch.com/healthcare/medical-devices/global-cancer-screening/172430-91.html
https://www.kenresearch.com/healthcare/medical-devices/europe-cancer-screening/172426-91.html
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
